Seattle Genetics Inc (SGEN) 49.21 $SGEN Takeda and

New Post Public Reply Private Reply Replies (0) Message Board

Aug 1, 2016 at 3:05 PM

Seattle Genetics Inc (SGEN) 49.21 $SGEN

Takeda and Seattle Genetics Announce Positive Data from Phase 3 ALCANZA Clinical Trial of ADCETRIS(R) (Brentuximab Vedotin) for CD30-Expressing Cutaneous T-Cell Lymphoma
BusinessWire - Mon Aug 01, 5:59AM CDT
---Abstract to be Submitted to ASH for Presentation at the 2016 Annual Meeting-
SGEN: 49.21 (+1.15)

Learn how to target a 13% return on Under Armour, or get option-trade ideas on SPDR Gold Trust, Seattle Genetics, Priceline and Lockheed Martin Corporation or any stock you choose
PR Newswire - Thu Jul 28, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GLD, LMT, PCLN, SGEN, and UA.
UA: 39.38 (-0.08), LMT: 253.39 (+0.66), SGEN: 49.21 (+1.15), GLD: 129.17 (+0.19), PCLN: 1,356.25 (+5.44)

Downgrade Alert for Seattle Genetics (SGEN)
Comtex SmarTrend(R) - Thu Jul 28, 3:49AM CDT
Seattle Genetics (NASDAQ:SGEN) was downgraded from Buy to Hold at Cantor today. The stock closed yesterday at $47.98 on volume of 1.4 million shares, above average daily volume of 954,000. There is potential upside of 3.6% for shares of Seattle Genetics based on a current price of $47.98 and an average consensus analyst price target of $49.69. The stock should find initial support at its 200-day moving average (MA) of $39.22 and further support at its 50-day MA of $35.07.
SGEN: 49.21 (+1.15)

Seattle Genetics' (SGEN) Loss Narrower than Expected in Q2
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 8:06AM CDT
Seattle Genetics (SGEN) reported a loss of 23 cents per share, narrower than both the Zacks Consensus Estimate of a loss of 33 cents.
SGEN: 49.21 (+1.15), BMY: 76.22 (+1.41)

Seattle Genetics Reports Second Quarter 2016 Financial Results
BusinessWire - Tue Jul 26, 3:02PM CDT
---Top-Line Data from ADCETRIS Phase 3 ALCANZA Trial Expected in Third Quarter of 2016-
SGEN: 49.21 (+1.15)

What's in Store for these 5 Drug Stocks in Q2 Earnings?
Arpita Dutt - Zacks Investment Research - Mon Jul 25, 7:24AM CDT
Medical stocks are once again expected be among the better performers in Q2. Johnson & Johnson (JNJ) and Biogen have already set the tone with beats and raised outlooks.
MDVN: 64.02 (+0.03), BIIB: 302.32 (+12.39), JNJ: 125.51 (+0.28), ALDR: 30.59 (-1.51), SGEN: 49.21 (+1.15), NEO: 8.53 (-0.19), EXAS: 17.95 (+0.57)

Seattle Genetics and Takeda Announce Publication of Final Data from ADCETRIS(R) (Brentuximab Vedotin) Monotherapy Pivotal Phase 2 Clinical Trial in Relapsed or Refractory Classical Hodgkin Lymphoma in Blood
BusinessWire - Mon Jul 18, 9:00AM CDT
---Patients Who Achieved a Complete Remission Had Estimated Five-Year Overall Survival of 64 Percent and Five-Year Progression-Free Survival of 52 Percent-
SGEN: 49.21 (+1.15)

AbbVie's ABT-414 Gets Rare Pediatric Disease Status in U.S.
Zacks Equity Research - Zacks Investment Research - Tue Jul 12, 9:19AM CDT
AbbVie's (ABBV) ABT-414 has been granted Rare Pediatric Disease Designation in the U.S. for the treatment of pediatric patients with EGFR-amplified DIPG.
INVA: 13.02 (+0.15), GWPH: 95.95 (+1.63), SGEN: 49.21 (+1.15), ABBV: 66.99 (+0.76)

Seattle Genetics/Takeda Adectris' Label Expanded in the EU
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 5:21PM CDT
Seattle Genetics, Inc. (SGEN) announced that its partner Takeda Pharmaceutical Company Limited (TKPYY) has received marketing authorization for the label expansion of its lymphoma drug, Adcetris.
JNJ: 125.51 (+0.28), SGEN: 49.21 (+1.15), PFE: 37.35 (+0.46)

Seattle Genetics Set to Possibly Pullback After Yesterday's Rally of 2.19%
Comtex SmarTrend(R) - Wed Jun 22, 2:54PM CDT
Seattle Genetics (NASDAQ:SGEN) traded in a range yesterday that spanned from a low of $38.06 to a high of $40.58. Yesterday, the shares gained 2.2%, which took the trading range above the 3-day high of $39.40 on volume of 396,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SGEN: 49.21 (+1.15)

Seattle Genetics Highlights Vadastuximab Talirine (SGN-CD33A) Data in Acute Myeloid Leukemia (AML) at the 21st Congress of the European Hematology Association
PR Newswire - Sat Jun 11, 1:30AM CDT
Seattle Genetics, Inc. (NASDAQ: SGEN) today highlighted data at the 21st Congress of the European Hematology Association (EHA) taking place in Copenhagen, Denmark, June 9-12, 2016, evaluating vadastuximab talirine (SGN-CD33A; 33A) in combination with hypomethylating agents (HMAs; azacitidine, decitabine) in frontline patients with acute myeloid leukemia (AML) who had declined intensive therapy. 33A is an investigational antibody-drug conjugate (ADC) targeted to CD33 utilizing Seattle Genetics' newest technology, comprising an engineered cysteine antibody (EC-mAb) stably linked to a highly potent DNA binding agent called a pyrrolobenzodiazepine (PBD) dimer. CD33 is expressed on leukemic blasts in nearly all AML patients with expression generally consistent regardless of age, cytogenetic abnormalities or underlying mutations.
SGEN: 49.21 (+1.15)

Seattle Genetics and Astellas Present ASG-15ME and Enfortumab Vedotin Phase I Clinical Data in Metastatic Urothelial Cancer at ASCO Annual Meeting
BusinessWire - Mon Jun 06, 7:00AM CDT
Seattle Genetics, Inc. (NASDAQ:SGEN) and Astellas Pharma Inc. (TOKYO:4503) today presented first clinical data for ASG-15ME and enfortumab vedotin (ASG-22ME) at the American Society of Clinical Oncology (ASCO) 51st Annual Meeting being held June 3-7, 2016, in Chicago, IL.
SGEN: 49.21 (+1.15)

Astellas and Seattle Genetics Present ASG-15ME and ASG-22ME Phase I Clinical Data in Metastatic Urothelial Cancer at ASCO Annual Meeting
PR Newswire - Mon Jun 06, 7:00AM CDT
Astellas Pharma Inc. (TSE: 4503) and Seattle Genetics, Inc. (NASDAQ: SGEN) today presented first clinical data for ASG-15ME and ASG-22ME at the American Society of Clinical Oncology (ASCO) 51st Annual Meeting being held June 3-7, 2016 in Chicago, IL.
SGEN: 49.21 (+1.15)

Seattle Genetics Rises 5.91% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Thu Jun 02, 2:37PM CDT
Seattle Genetics (NASDAQ:SGEN) traded in a range yesterday that spanned from a low of $40.40 to a high of $43.37. Yesterday, the shares gained 5.9%, which took the trading range above the 3-day high of $41.14 on volume of 663,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SGEN: 49.21 (+1.15)

Seattle Genetics Starts Trial on Acute Myeloid Leukemia Drug
Zacks Equity Research - Zacks Investment Research - Thu May 26, 2:59PM CDT
Seattle Genetics, Inc. (SGEN) announced that it has initiated a phase III trial, CASCADE, on vadastuximab talirine (SGN-CD33A).
ABT: 45.38 (+0.63), JNJ: 125.51 (+0.28), SGEN: 49.21 (+1.15), SNY: 42.61 (-0.02)

Seattle Genetics Initiates Pivotal Phase 3 Trial of Vadastuximab Talirine (SGN-CD33A) for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
BusinessWire - Wed May 25, 7:00AM CDT
---Data Presented at the 2015 American Society of Hematology Annual Meeting Demonstrated Encouraging Anti-leukemic Activity and Support Advancing 33A into a Registrational Trial-
SGEN: 49.21 (+1.15)

What to Look for in These Biotech Stocks? Threshold Pharma, Seattle Genetics, Chiasma, and Ophthotech
PR Newswire - Wed May 18, 7:38AM CDT
The Biotech industry continues to face a wave of challenges, but it does not mean that there are no opportunities ahead. Today, ActiveWallSt.com has on its list these four equities: Threshold Pharmaceuticals Inc. (NASDAQ: THLD), Seattle Genetics Inc. (NASDAQ: SGEN), Chiasma Inc. (NASDAQ: CHMA), and Ophthotech Corp. (NASDAQ: OPHT). Sign up now to receive our free insights and trading alerts at:
SGEN: 49.21 (+1.15), OPHT: 64.59 (+0.35), THLD: 0.50 (-0.01), CHMA: 2.75 (+0.10)

Taking Inventory on Seattle Genetics, Inc. Earnings
Brian Orelli, The Motley Fool - Motley Fool - Wed May 04, 5:04PM CDT
Seattle Genetics released first-quarter earnings results on Thursday, and while sales of Adcetris continued to grow, they weren't quite as robust as investors were hoping for. Seattle Genetics results: The raw numbers ...
SGEN: 49.21 (+1.15)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Monster Energy Dominates Skateboard Podium at SLS Paris

Monster Energy's Skateboard Triumph Hold the front page, because Monster Energy just pulled off a clean sweep in Paris. The company's team riders dominated the Men's Skateboard Street competition at the SLS Paris 2026, with the iconic Nyjah Huston snagging the top spot. It's a story filled with triumph, grit, and a dash of raw talent in a vibrant field of international...

Black Culture Icon: Plastic-Covered Couch Takes Stage

A Plastic-Laden Piece of History Makes Art Who'd have thought a plastic-covered couch would turn into a cultural artifact? This iconic staple in Black households has done just that, debuting at Brooklyn's CultureCon in a fresh guise. It's more than just an upcycled furniture piece; it's a living archive that encapsulates Black culture, joy, and resilience. The Heart...

Monteverde Probes Four Key M&A Deals for Fairness

Examining the Intricacies of Pending M&A The merger and acquisition landscape can be vicious, especially when the sharks—those pesky class action lawyers—start circling. And let me tell you, Monteverde & Associates PC is diving headfirst into the fray, launching inquiries into a handful of these deals. This isn't your first stroll down Wall Street if you’ve seen one...

Power Knot MEA Wins THE BIZZ 2026 for Excellence

Setting the Pace in Waste Management If there's one thing that sticks in my craw, it's how businesses handle food waste. Power Knot Middle East (PKME) seems to have cracked the code by not just leading the charge in organic waste management but also bagging THE BIZZ 2026 award. They’re not just playing industry games; PKME's pulling the strings with real leadership and...

ARTBOX Brings Korean Lifestyle Magic to LA Pop-Up

ARTBOX: From Seoul to La-La Land Here's what caught my eye. It's 2026, and Korean lifestyle retailer ARTBOX is making a splash in the U.S.—kicking things off with a pop-up in LA. Now, usually, I'd be skeptical about pop-ups, but you've got to admire the audacity and timing here. They've picked Melrose Avenue, a hotspot for all things trendy, to introduce their mix of...

SiBionics and PharmaSens Unveil Diabetes Tech at EASD

Shaking Up Diabetes Care: New Tech Unveiled Imagine a world where managing diabetes isn't a juggling act with multiple devices. That's precisely the future SiBionics and PharmaSens are pitching at the European Association for the Study of Diabetes (EASD) 2026 in Milan. Now, let me tell you, these guys aren't just playing around with ideas; they're aiming to radically...

Unpacking Monteverde's M&A Investigations Hold your horses, folks! The M&A Class Action Firm is stirring the pot with its latest inquiries into some high-profile mergers. We're looking at Lisata Therapeutics, Flag Ship Acquisition Corporation, Baldwin Insurance Group, and ACV Auctions. So what's got Juan Monteverde's legal eagles swooping in on these deals? Well, are we...

Lawsuit Highlights Inaction in School Bus Tragedy

Seeking Justice Amid Heartbreak Tragedy rarely arrives whispered on the wind—more often, it's the train wreck some saw coming long before it hits. The tragic death of Jenna Menias, a 6-year-old from Frankfort, Illinois, falls squarely in this camp. The family's legal lions, Corboy & Demetrio, have slapped two school districts—District 210 and 157-C—with a wrongful...

Blokees Unveils 90+ New Wonders at Shanghai Fest

A Grand Stage for New Arrivals Picture this: In the bustling and glittering chaos that was the Wonder Festival Shanghai 2026, held from October 3 to 4, Blokees laid down a major marker. More than 500 products, an artillery of imagination and craftsmanship, were on deck across their key lines—Blokees Model Kits and BLOKEES WHEELS. With 90 brand-new creations making their...

Monteverde's Equity Alert: Scrutinizing Recent M&A Deals

Diving Into M&A Deals Under Monteverde's Lens Wall Street’s not just about suits and skyscrapers; it’s about the nitty-gritty of deals and whether those numbers add up in the investor's favor. So, when Monteverde & Associates PC throws its weight into scrutinizing mergers and acquisitions, you better believe it's worth a second look. See, they’re digging into four...